


- Carprovet Caplets are indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative pain associated with soft tissue and orthopedic surgeries in dogs.
- Therapeutically equivalent to the pioneer drug so you can expect the same safety and efficacy.
- Backed by the Dechra Veterinary Technical and Sales Support Teams.
- Available in 25 mg, 75 mg, and 100 mg scored caplets in 60 and 180 count bottles.



Carprovet Caplets vs. Rimadyl® Caplets



To order, please contact your Dechra or distributor representative or call (866) 683-0660. For more information, please visit www.dechra-us.com

Important Safety Information: As with other NSAIDs, signs of carprofen intolerance may include appetite loss, vomiting and diarrhea, which could indicate side effects involving the digestive tract, liver or kidneys. Some of these side effects, in rare situations, may be serious, resulting in hospitalization or even death. Pet owners should be advised to discontinue treatment if side effects occur and contact their veterinarian. Concomitant use of Carprofen Caplets with other anti-inflammatory drugs, such as other NSAIDs or corticosteroids, should be avoided because of the potential increase of adverse reactions. Refer to the prescribing information and "Dog Owner Information Sheet" for complete details or visit www.dechra-us.com.


24-hour Veterinary Technical Support available (866) 933-2472. Nonurgent Technical Support available via email support@dechra.com.

Dechra is a registered trademark of Dechra Pharmaceuticals PLC. Rimadyl[®] is a registered trademark of Zoetis Services, LLC. 05PG-CAR50058-0419

ANADA 200-397, Approved by FDA CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Carprovet[®] (carprofen) Caplets Non-steroidal anti-inflammatory drug For oral use in dogs only

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DBSCRIPTION: Carprover (carprotein card) was been of the order of the acetic acid. The empirical formula is $C_{\rm 15}H_{\rm 12}CINO_2$ and the molecular weight 273.72 The chemical structure of carprofen is:



Carprofen is a white, crystalline compound. It is freely soluble in ethanol, but practically

Carporter is a wrine, crystaline compound. In is needy soluble in entation, outpradicativy H isoluble in water at 25°C. CLINICAL PHARMACOLOGY: Carporlen is a non-narcolic, non-steroidal anti-inflammatory agent with characteristic analgesic and antipyretic activity approximately equipotent to indomethanian in animal models'. The mechanism of action of carporlen, like that of other NSAIDs, is believed to be associated with the inhibition of cyclooxygenase activity. Two unique cyclooxygenases have been described in mammalos.² The constitutive cyclooxygenase, COX-2, perivates prostaglandins involved in inflammation. Inhibition of COX-1 is subject to be associated with gastronistication and that an enal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is subject to be associated with gastronisticatinal and renal function. The inducible cyclooxygenase, COX-2, generates prostaglandins involved in inflammation. Inhibition of COX-1 is subject to be associated with gastronisticatinal and renal function. The inducible cyclooxygenase, coxies and the cycle of these data has not been shown. Carprofen has also been shown to inhibit the release of several prostaglandins in two inflammatory cell systems: rat polymorphonuclear leukocytes (PMN) and human rheumaticid synowith data obtained relist indicating inhibition of effects on both humoral and cellular immune responses.⁴⁵ Data also indicate that carprofen inhibits the production of ostocalast-activating factor (OAP), PGE1, and PGE2 by its inhibitory effects on prostaglandin biosynaving from 1.35 mg/kg to dogs. The mean terminal half-life darprofen is approximately 8 hours achieved in 1-3 hours after oral administration or 1, 5, and 25 mg/kg to dogs. The mean terminal half-life darprofen is approximately 8 hours elimination half-life was approximately 11.7 hours in the dog. Carprofen is more than 99% bound to plasma protein and exhibits a very small outure of distribution.

Carprofen is eliminated in the dog primarily by biotransformation in the liver followed by rapid excretion of the resulting metabolites (the ester journalise of carprofer and the effect of the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative (70-80%) and urine (10-20%). Some enterohepatic circulation of the drug is observed. INDICATIONS: Carprovet is indicated for the relief of pain and inflammation associated with osteoarthritis and for the control of postoperative

an associated with soft issue and orthopedic surgeries in dogs. CONTRAINDICATIONS: Carprovet should not be used in dogs exhibiting previous hypersensitivity to carprofen. WARNINGS: Keep out of reach of children. Not for human use. Consult a physician in cases of accidental ingestion by humans. For use in dogs only. Do not use in cats.

WARNINGS: Keep out of reach of children. Not for human use. Consult a physician in cases of accidental ingestion by humans. For use in dogs only. Do not use in cats. All dogs should undergo a thorough history and physical examination before initiation of NSAID therapy. Appropriate laboratory tests to establish hematological and serum biochemical baseline data prior to, and periodically during, administration of any NSAID should be considered. **Owners** should be advised to observe for signs of potential drug toxicity (see INFORMATION FOR DOG OWNERS, ADVERSE **RECATIONS**, ANIMAL SAFETY and POST-APPROVAL EXPERIENCE). PRECAUTIONS: As a class, cyclooxygenase inhibitory NSAID may be associated with gastrointestinal, renal and hepatic toxicity. Effects may result from decreased prostaglandin production and inhibition of the enzyme cyclooxygenase which is responsible for the formation of prostaglandins from arachiconic add. ¹¹⁻¹⁴ When NSAID inhibit prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandins that cause inflammation they may also inhibit those prostaglandins which maintain normal homeostatic function. These anti-prostaglandins therapy could urmask occult disease in patients with underlying or pre-existing disease more often than in healthy patients.¹¹⁻¹⁴ NSAI therapy could urmask occult disease in patients with underlying and approxed but to the absence of apparent clinical signs. Patients with underlying rerula disease for example, may experience exacethation or decompensation of their renal disease while on NSAID breapy.¹¹⁻¹⁴ The use of parenteral fluxids during surgery should be considered to reduce gastrointestimal signs. Events involving suspected eneal, hermatologic, neurologic, dermatologic, and hepatic fields have been gastrointestima signs. Events involving suspected eneal, hermatologic, neurologic, dermatologic, and hepatic therapy, or those with renal, caradiovascular, and/ ar hepat

varies with the individual patient. Dogs that have experienced adverse reactions from one NSAID may experience adverse reactions from another NSAID. Carprofen treatment was not associated with renal toxicity or gastrointestinal ulceration in well-controlled safety studies of up to ten times the dose in healthy dogs. Carprofen is not recommended for use in dogs with bleeding disorders (e.g., Von Willebrand's disease), as safety has not been established in dogs with these disorders. The safe use of carprofen in animals less than 6 weeks of age, preparant dogs, dogs used thoresed dogs with these disorders. The safe use of carprofen in animals less than 6 weeks of age, preparant dogs, dogs used thoresed bound or similarly metabolized drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring additional therapy. Such drugs commonly used include cardiac, anticonvulsant and behavioral medications. It has been suggested that treatment with carprofen may reduce variant daministration of the total daily dose of carprofen, alternative analgesia should be considered. The use of another NSAID is not recommended. Consider appropriate washout times when switching from one NSAID to another or when switching from corticosterioid use to NSAID use.

in NSΔID use

The consistence of the constraint of the constra reported. The product vehicle served as control

Placebo (n=132) 6 1.5 1 3.8
•
1 3.8
1 4.5
8 0.8
8 0.8
8 –
8 8.3
4 4.5
3 0.8
1 1.5
.3 12.1
.7 9.1

ers listed represent reports of increases from pre-treatment values; medical judgment is necessary to determine clinical relevance

United inclusion and a served as control.

Percentage of Dogs with Abnormal Health Observations Reported in Surgical Pain Field Studies with Caplets (2 mg/lb once daily)			
Observation*	Carprofen (n=148)	Placebo (n=149)	
Vomiting	10.1	13.4	
Diarrhea/Soft stool	6.1	6.0	
Ocular disease	2.7	0	
Inappetence	1.4	0	
Dermatitis/Skin lesion	2.0	1.3	
Dysrhythmia	0.7	0	
Apnea	1.4	0	
Oral/Periodontal disease	1.4	0	
Pyrexia	0.7	1.3	
Urinary tract disease	1.4	1.3	
Wound drainage	1.4	0	

* A single dog may have experienced more than one occurrence of an event

Post-Approval Experience: Although not all adverse reactions are reported, the following adverse reactions are based on voluntary post-approval adverse drug experience reporting. The categories of adverse reactions are listed in decreasing order of frequency by body system. Gastrointestinal: Vomiting, diarrhea, constipation, inappetence, melena, hematemesis, gastrointestinal ulceration, gastrointestinal

Castrolinestinal: Voiniting, cliarrhea, constipation, inappetence, mèlena, hematemesis, gastrointestinal ulceration, gastrointestinal bleeding, pancreatitis. Hepatic: Inappetence, vomiting, jaundice, acute hepatic toxicity, hepatic enzyme elevation, abnormal liver function test(s), hyperbilirubinemia, bilirubinuria, hypoabuminemia. Approximately one-fourth of hepatic reports were in Labrador Retrievers. Neurologic: Ataxia, paresis, paralysis, seizures, vestbular signs, disorientation. Urinary: Hematuria, polydipsia, urinary incontinence, ucurinary tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necosis, renal tubular acidosis, gueurs y tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necosis, renal tubular acidosis, gueurs any tract infection, azotemia, acute renal failure, tubular abnormalities including acute tubular necosis, renal tubular acidosis, gueurs and the acute senses. Behavioral: Sedation, lethargy, hyperactivity, restlessness, aggressiveness. Hematologic: Immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, blood loss anemia, epistaxis. Dermatioogic: Puritus, increased shedding, alopecia, pyotraumatic moist dermatitis (hot spots), necrotizing panniculitis/vasculitis, ventral ecclymosis.

Immunologic or hypersensitivity: Facial swelling, hives, erythema. In rare situations, death has been associated with some of the adverse reactions listed above. To report suspected adverse events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Dechra at (866) 933-2472

933-2412. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or http://www.fda.gov/Animal/Veterinary/SafetyHealth DOSAGE AND DOMINISTERTATION: Anways provide Client Information Sheet with prescription. Carefully consider the potential benefits and risk of Carprovet and other treatment options before deciding to use Carprovet. Use the lowest effective dose for the shortest duration consistent with individual response. The recommended dosage for oral administration to dogs is 2 mg/b(4.4 mg/bg) of body weight daily. The total daily dose may be administered as 2 mg/b) of body weight once daily or divided and administered as 1 mg/b (2.2 mg/bg) twice daily. For the control of postoperative pain, administer approximately 2 hours before the procedure. Carprovet caplets are scored and dosage should be calculated in bit-carel increments.

Trait-capiet increments. EFFECTIVENESS: Confirmation of the effectiveness of carprofen for the relief of pain and inflammation associated with osteoarthritis, and for the control of postoperative pain associated with soft tissue and orthopedic surgeries was demonstrated in 5 placebo-controlled, masked studies examining the anti-inflammatory and analgesic effectiveness of carprofen capiets in various breeds of dogs. Separate placebo-controlled, masked, multicenter field studies confirmed the anti-inflammatory and analgesic effectiveness of carprofen capiets when doxed at 2 mg/h0 none daily or when divided and administered at 1 mg/h twice daily. In these two field studies, dogs diagnosed with osteoarthritis showed statistically significant overall improvement based on lameness evaluations by the veterinarian and owner observations when administered carprofen at block doncess. labeled doses.

significant overall improvement based on lameñess evaluations by the veterinarian and owner observations when administered carprofen at labeled doses. Separate placebo-controlled, masked, multicenter field studies confirmed the effectiveness of carprofen caplets for the control of postoperative pain when dosed at 2 mg/b once daily in various breeds of dogs. In these studies, dogs presented for variohysterectomy, cruciate repair and aural surgeises were administered carprofen repertively and for a maximum of 3 days (stit tissue) or 4 days (orthopedic) postoperatively, in general, dogs administered carprofen showed statistically significant improvement in pain scores compared to controls. **AMIMAL SAFETY:** Laboratory studies in unanesthetized dogs and clinical field studies have demonstrated that carprofen is well tolerated in dogs after oral administration. In target animal safety studies, carprofen was administered orally to healthy Beagle dogs at 1, 3, and 5 mg/b twice daily (1, 3 and 5 times the recommended total daily doss) for 42 consecutive days with no significant adverse reactions. Serum albumin for a single female dog receiving 5 mg/lb twice daily careased to 2.1 g/dL after 2 weeks of treatment, returned to the pre-treatment preid, back or bloody stools were observed in 1 dog (1 incident) treated with 1 mg/b twice daily and in 1 dog (2 incidents) treated with 3 mg/b twice daily. Redness of the colonic mucosa was observed in 1 mg/b twice daily (10 times the recommended total daily dose) for 14 days exhibited hypoalbuminemia. The mean abumin level in the dogs receiving this dose was lower (2.38 g/dL) than each of 2 placebo control groups (2.88 and 2.93 g/dL, sol to alw groups were dails, 1.9 were 3 dogs to 2.1 g/dL, if 2 weeks, respectively, were 3 doserved in 1 dug bal of the arimatis. No groos or pross pathologic examination. Histologic examination of these areas revealed no evidence of ulceration, but did show minimal congestion of the arimate safety studies lasting 13 and 52 weeks, respectively, dogs w

Clinical field studies were conducted with 549 dogs of different breeds at the recommended oral doses for 14 days (297 dogs were included in a separate study evaluating 2 mg/lb once daily.) In both studies the dog was clinically well tolerated and the incidence of clinical adverse reactions for carprofen-treated animals was no higher than placebo-treated animals (placebo contained inactive ingredients found in carprofen). For animals receiving 1 mg/lb twice daily, the mean post-treatment serum ALT values were 11 IU greater and 9 IU less than pre-treatment values for dogs receiving approximation and placebo, respectively. Differences were not statistically significant. For animals receiving 2 mg/lb once daily, the mean post-treatment serum ALT values were 4.5 IU greater and 0.9 II less than pre-treatment values for dogs receiving carprofen-treated dogs developed a 3-fold or greater increase in (ALT) and/or (AST) during the course of therapy. One hackbo, respectively. Differences were not statistically significant. For animals receiving 2 mg/lb once daily, the mean post-treatment serum ALT values were 4.5 IU greater and 0.9 II less than pre-treatment and/or diving the course of therapy. One hackbo, respectively. In the latter study, 3 carprofen-treated dogs developed a 3-fold or greater increase in ALT. None of these animals showed clinical signs associated with laboratory value changes. Changes in the clinical laboratory value changes. Changes in the clinical laboratory value changes.

increase in ALT. None of these animals showed clinical signs associated with laboratory value changes. Changes in the clinical laboratory values (nematology and clinical chemistry) were not considered clinically significant. The 1 mg/b twice daily course of therapy was repeated as needed at 2-week intervals in 244 dogs, some for as long as 5 years. Clinical field studies were conducted in 297 dogs of different breeds undergoing orthopedic or soft tissue surgery. Dogs were administered 2 mg/b of carryofen two hours prior to surgery then nonce daily as needed for 2 days (soft tissue surgery) or 3 days (orthopedic surgery). Carprofen was well tolerated when used in conjunction with a variety of anesthetic-related drugs. The type and severity of abnormal health observations in carprofen-and placebo-treated animals were approximately equal and few in number (see Adverse Reactions). The most frequent abnormal health observation was vomiting and was observed at approximately the sure frequency in carprofen-and placebo-treated animals. Changes in clinicopathologic indices of hematopoletic, renal, hepatic, and doiting function were not dinically significant. The mean post-treatment server AI trad ace 5.1 Ull ess for dogs receiving carprofen and 0.2 IU greater for dogs receiving placebo. **STORAGE:** Store at controlled room temperature: 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F).

BOPH, HOW SUPPLIED: Carprovet caplets are scored, and contain 25 mg, 75 mg, or 100 mg of carprofen per caplet. Each caplet size is packaged in bottles containing 60 or 180 caplets. Carprovet Caplets 25 mg, 60 caplets NDC-17033-362-60, Carprovet Caplets 25 mg, 180 caplets NDC-17033-362-18 Carprovet Caplets 75 mg, 60 caplets NDC-17033-367-60, Carprovet Caplets 75 mg, 180 caplets NDC-17033-367-18 Carprovet Caplets 100 mg, 60 caplets NDC-17033-361-60, Carprovet Caplets 75 mg, 180 caplets NDC-17033-367-18

 Baruth H, et al: In Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. II, Newer Anti-Inflammatory Drugs, Rainsford KD, ed. CRC Press, Boca Raton, pp. 33-47, 1986.
 Baruth H, et al: In Anti-Inflammatory and Anti-Rheumatic Drugs, Vol. II, Newer Anti-Inflammatory Drugs, Rainsford KD, ed. CRC Press, Boca Raton, pp. 33-47, 1986.
 Vane JR, Botting RM. Mechanism of action of anti-Inflammatory drugs. Scand J Rheumatol 25:102, pp. 9-21.
 Grossman CJ, Wiseman J, Lucas FS, et al: Inhibition of constitutive and indubile cyclooxygenase activity in human platelets and mononuclear cells by NSAIDs and Cox2: Unitibitors. Inflammation Research 44:253-257, 1995.
 Ricketts AP, Lundy KM, Seibel SB: Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 59:11, pp. 1441-1446, November 1998.
 Ceuppens JL, et al: Endogenous prostaglandin E2 enhances polyclonal immunoglobulin production by ionically inhibiting T suppressor cell activity. Cell Immunol 70:41, 1982.
 Schleimer RP, et al: The effects of prostaglandin synthesis inhibition on the immune response. Immunopharmacology 3:205, 1981.
 Leung KH, et al: Modulation of the development of cell mediated immunity: possible roles of the products of cyclooxygenase and Ipoxygenase pathways of rachichoria acid metabolism. Int L Immunopharmacology 4:1962.
 Vet BC: Immunoregulatory activity of cultured-induced suppressor macrophages. Cell Immunol 72:14, 1982.
 Schnitt M, et al: Biopharmacoutical evaluation of carprofer following single intravenous, oral, and rectal doses in dogs. Biopharm Drug Dipoxg 11(7): 586-94, 1990.
 Kore AW: Toxicology of nonsteroidal anti-inflammatory drugs. Veterinary Clinics of North America, Small Animal Practice 20, March 1990.
 Kore AW: Toxicology of nonsteroidal anti-inflammatory drugs. Veterinary Clinics of North America, Small Animal Pr **REFERENCES:**

- 12. Binns SH: Pathogenesis and pathophysiology of ischemic injury in cases of acute renal failure. Compend for Cont Ed 16:1, January

- H994.
 Boothe DM: Prostaglandins: Physiology and clinical implications. Compend for Cont Ed 6:11, November 1984.
 Robin SI: Nonsteroidal anti-inflammatory drugs, prostaglandins, and the kidney. JAVMA 188:9, May 1986.
 Ko CH, Lange DN, Mandsager RE, et al: Effects of butorphanol and carprofen on the minimal alveolar concentration of isoflurane in dogs. JAVMA 217:1025-1028, 2000.
 For a copy of the Material Safety Data Sheet (MSDS) or to report adverse reactions call: (866) 933-2472.
 ANADA 200-397, Approved by FDA



Manufactured for: Dechra Veterinary Products 7015 College Boulevard, Suite 525, Overland Park, KS 66211 USA

By: Belcher Pharmaceuticals, LLC 6911 Brvan Dairy Road, Suite 210, Largo, Florida 33777 USA Rev. September 2018

